San Diego, CA (PRWEB) May 20, 2013
Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Robert L. Wilensky, MD, Professor of Medicine and Director of Interventional Cardiology Research at the University of Pennsylvania has agreed to join the Scientific and Medical Advisory Board for Stemedica’s Cardiology Division.
At the University of Pennsylvania, Dr. Wilensky divides his time between the cardiac catheterization laboratories and the translational animal laboratory. His research interests include acute coronary syndromes, diagnosis and treatment of vulnerable coronary lesions and stem cell therapy for decreased left ventricular function and coronary artery disease.
Stephen Epstein, MD, Chairman of Stemedica’s Cardiology Division Scientific and Medical Advisory Board commented, “Dr. Wilensky’s strong interest and expertise in both interventional cardiology and translational medicine, most notably with stem cells, parallels and strongly supports the direction we are taking with Stemedica.”
Dr. Wilensky received his MD degree with distinction from the University of Amsterdam. His internship and residency in Internal Medicine was obtained at the Georgetown University Medical Center in Washington, DC. His fellowship in Cardiology was at the Krannert Institute of Cardiology, Indiana University, where he was Chief Fellow and later Assistant Professor of Medicine. He joined the faculty of the University of Pennsylvania in 1996.
Dr. Wilensky has been an active organizer of, and participant in, many international cardiology symposia, including the Cardiovascular Revascularization Therapies meetings and Transcatheter Therapeutics Meetings. He has lectured
Copyright©2012 Vocus, Inc.
All rights reserved